



US010098591B2

(12) **United States Patent**
Al-Ali et al.

(10) **Patent No.:** **US 10,098,591 B2**
(45) **Date of Patent:** **Oct. 16, 2018**

(54) **PHYSIOLOGICAL PARAMETER SYSTEM**

(71) Applicant: **Masimo Corporation**, Irvine, CA (US)

(72) Inventors: **Ammar Al-Ali**, San Juan Capistrano, CA (US); **John Graybeal**, Grantville, PA (US); **Massi Joe E. Kiani**, Laguna Niguel, CA (US); **Michael Petterson**, Dana Point, CA (US)

(73) Assignee: **Masimo Corporation**, Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 447 days.

(21) Appl. No.: **14/275,525**

(22) Filed: **May 12, 2014**

(65) **Prior Publication Data**

US 2014/0330092 A1 Nov. 6, 2014

Related U.S. Application Data

(60) Division of application No. 12/188,154, filed on Aug. 7, 2008, now Pat. No. 8,721,542, which is a continuation of application No. 11/075,389, filed on Mar. 8, 2005, now Pat. No. 7,415,297.

(60) Provisional application No. 60/551,165, filed on Mar. 8, 2004, provisional application No. 60/600,640, filed on Aug. 11, 2004.

(51) **Int. Cl.**

A61B 5/00 (2006.01)

A61B 5/1455 (2006.01)

A61B 5/083 (2006.01)

(52) **U.S. Cl.**

CPC **A61B 5/7275** (2013.01); **A61B 5/14551** (2013.01); **A61B 5/7221** (2013.01); **A61B 5/746** (2013.01); **A61B 5/0836** (2013.01); **A61B 2560/0276** (2013.01)

(58) **Field of Classification Search**

CPC combination set(s) only.

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,453,218 A 6/1984 Sperinde et al.
4,729,381 A * 3/1988 Harada A61B 5/0205
346/33 ME

4,960,128 A 10/1990 Gordon et al.
4,964,408 A 10/1990 Hink et al.
5,041,187 A 8/1991 Hink et al.

(Continued)

FOREIGN PATENT DOCUMENTS

WO WO 98/10699 3/1998
WO WO 03/053503 A1 7/2003
WO WO 2005056087 A1 * 6/2005 A61M 5/1723

OTHER PUBLICATIONS

US 8,845,543, 09/2014, Diab et al. (withdrawn)

(Continued)

Primary Examiner — John R Downey


Assistant Examiner — Shirley Jian

(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear, LLP

(57) **ABSTRACT**

A physiological parameter system has one or more parameter inputs responsive to one or more physiological sensors. The physiological parameter system may also have quality indicators relating to confidence in the parameter inputs. A processor is adapted to combine the parameter inputs, quality indicators and predetermined limits for the parameters inputs and quality indicators so as to generate alarm outputs or control outputs or both.

4 Claims, 8 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

5,069,213 A	12/1991	Polczynski	6,151,516 A	11/2000	Kiani-Azarbayjany et al.
5,123,420 A	6/1992	Paret	6,152,754 A	11/2000	Gerhardt et al.
5,163,438 A	11/1992	Gordon et al.	6,157,850 A	12/2000	Diab et al.
5,319,355 A	6/1994	Russek	6,165,005 A	12/2000	Mills et al.
5,337,744 A	8/1994	Branigan	6,184,521 B1	2/2001	Coffin, IV et al.
5,341,805 A	8/1994	Stavridi et al.	6,206,830 B1	3/2001	Diab et al.
D353,195 S	12/1994	Savage et al.	6,215,403 B1	4/2001	Chan et al.
D353,196 S	12/1994	Savage et al.	6,229,856 B1	5/2001	Diab et al.
5,377,676 A	1/1995	Vari et al.	6,232,609 B1	5/2001	Snyder et al.
D359,546 S	6/1995	Savage et al.	6,236,872 B1	5/2001	Diab et al.
5,431,170 A	7/1995	Mathews	6,241,683 B1	6/2001	Macklem et al.
D361,840 S	8/1995	Savage et al.	6,253,097 B1	6/2001	Aronow et al.
D362,063 S	9/1995	Savage et al.	6,256,523 B1	7/2001	Diab et al.
5,452,717 A	9/1995	Branigan et al.	6,263,222 B1	7/2001	Diab et al.
D363,120 S	10/1995	Savage et al.	6,278,522 B1	8/2001	Lepper, Jr. et al.
5,456,252 A	10/1995	Vari et al.	6,280,213 B1	8/2001	Tobler et al.
5,479,934 A	1/1996	Imran	6,285,896 B1	9/2001	Tobler et al.
5,482,036 A	1/1996	Diab et al.	6,301,493 B1	10/2001	Marro et al.
5,490,505 A	2/1996	Diab et al.	6,317,627 B1	11/2001	Ennen et al.
5,494,043 A	2/1996	O'Sullivan et al.	6,321,100 B1	11/2001	Parker
5,533,511 A	7/1996	Kaspari et al.	6,325,761 B1	12/2001	Jay
5,534,851 A	7/1996	Russek	6,334,065 B1	12/2001	Al-Ali et al.
5,561,275 A	10/1996	Savage et al.	6,337,629 B1	1/2002	Bader
5,562,002 A	10/1996	Lalin	6,343,224 B1	1/2002	Parker
5,590,649 A	1/1997	Caro et al.	6,349,228 B1	2/2002	Kiani et al.
5,602,924 A	2/1997	Durand et al.	6,360,114 B1 *	3/2002	Diab A61B 5/14551 600/336
5,632,272 A	5/1997	Diab et al.	6,368,283 B1	4/2002	Xu et al.
5,638,816 A	6/1997	Kiani-Azarbayjany et al.	6,371,921 B1	4/2002	Caro et al.
5,638,818 A	6/1997	Diab et al.	6,377,829 B1	4/2002	Al-Ali
5,645,440 A	7/1997	Tobler et al.	6,388,240 B2	5/2002	Schulz et al.
5,685,299 A	11/1997	Diab et al.	6,397,091 B2	5/2002	Diab et al.
D393,830 S	4/1998	Tobler et al.	6,430,437 B1	8/2002	Marro
5,743,262 A	4/1998	Lepper, Jr. et al.	6,430,525 B1	8/2002	Weber et al.
5,758,644 A	6/1998	Diab et al.	6,449,501 B1	9/2002	Reuss
5,760,910 A	6/1998	Lepper, Jr. et al.	6,463,311 B1	10/2002	Diab
5,769,785 A	6/1998	Diab et al.	6,470,199 B1	10/2002	Kopotic et al.
5,782,757 A	7/1998	Diab et al.	6,501,975 B2	12/2002	Diab et al.
5,785,659 A	7/1998	Caro et al.	6,505,059 B1	1/2003	Kollias et al.
5,791,347 A	8/1998	Flaherty et al.	6,515,273 B2	2/2003	Al-Ali
5,810,734 A	9/1998	Caro et al.	6,519,487 B1	2/2003	Parker
5,823,950 A	10/1998	Diab et al.	6,525,386 B1	2/2003	Mills et al.
5,830,131 A	11/1998	Caro et al.	6,526,300 B1	2/2003	Kiani et al.
5,833,618 A	11/1998	Caro et al.	6,541,756 B2	4/2003	Schulz et al.
5,860,919 A	1/1999	Kiani-Azarbayjany et al.	6,542,764 B1	4/2003	Al-Ali et al.
5,890,929 A	4/1999	Mills et al.	6,580,086 B1	6/2003	Schulz et al.
5,895,371 A *	4/1999	Levitas A61M 5/1723 604/500	6,584,336 B1	6/2003	Ali et al.
5,904,654 A	5/1999	Wohlmann et al.	6,595,316 B2	7/2003	Cybulski et al.
5,919,134 A	7/1999	Diab	6,597,932 B2	7/2003	Tian et al.
5,934,925 A	8/1999	Tobler et al.	6,597,933 B2	7/2003	Kiani et al.
5,940,182 A	8/1999	Lepper, Jr. et al.	6,606,511 B1	8/2003	Ali et al.
5,957,885 A *	9/1999	Bollish A61M 5/1723 604/67	6,632,181 B2	10/2003	Flaherty et al.
5,995,855 A	11/1999	Kiani et al.	6,639,668 B1	10/2003	Trepagnier
5,997,343 A	12/1999	Mills et al.	6,640,116 B2	10/2003	Diab
6,002,952 A	12/1999	Diab et al.	6,643,530 B2	11/2003	Diab et al.
6,005,658 A *	12/1999	Kaluza A61B 5/145 356/39	6,650,917 B2	11/2003	Diab et al.
6,010,483 A *	1/2000	Spencer A61M 5/172 604/151	6,654,624 B2	11/2003	Diab et al.
6,011,986 A	1/2000	Diab et al.	6,654,632 B2 *	11/2003	Lange A61B 5/0478 600/544
6,027,452 A	2/2000	Flaherty et al.	6,658,276 B2	12/2003	Kiani et al.
6,036,642 A	3/2000	Diab et al.	6,661,161 B1	12/2003	Lanzo et al.
6,045,509 A	4/2000	Caro et al.	6,671,531 B2	12/2003	Al-Ali et al.
6,053,887 A *	4/2000	Levitas A61M 5/1723 604/500	6,678,543 B2	1/2004	Diab et al.
6,067,462 A	5/2000	Diab et al.	6,684,090 B2	1/2004	Ali et al.
6,081,735 A	6/2000	Diab et al.	6,684,091 B2	1/2004	Parker
6,088,607 A	7/2000	Diab et al.	6,697,656 B1	2/2004	Al-Ali
6,110,522 A	8/2000	Lepper, Jr. et al.	6,697,657 B1	2/2004	Shehada et al.
6,124,597 A	9/2000	Shehada	6,697,658 B2	2/2004	Al-Ali
6,128,521 A	10/2000	Marro et al.	RE38,476 E	3/2004	Diab et al.
6,129,675 A	10/2000	Jay	6,699,194 B1	3/2004	Diab et al.
6,144,868 A	11/2000	Parker	6,714,803 B1 *	3/2004	Mortz A61B 5/14551 600/323
			6,714,804 B2	3/2004	Al-Ali et al.
			RE38,492 E	4/2004	Diab et al.
			6,721,582 B2	4/2004	Trepagnier et al.
			6,721,585 B1	4/2004	Parker
			6,725,075 B2	4/2004	Al-Ali
			6,728,560 B2	4/2004	Kollias et al.
			6,735,459 B2	5/2004	Parker

(56)

References Cited

U.S. PATENT DOCUMENTS

6,745,060 B2	6/2004	Diab et al.	
6,751,499 B2 *	6/2004	Lange	A61B 5/0478 600/300
6,757,558 B2 *	6/2004	Lange	A61B 5/0478 600/544
6,760,607 B2	7/2004	Al-Ali	
6,768,920 B2 *	7/2004	Lange	A61B 5/0478 600/300
6,770,028 B1	8/2004	Ali et al.	
6,771,994 B2	8/2004	Kiani et al.	
6,792,300 B1	9/2004	Diab et al.	
6,813,511 B2	11/2004	Diab et al.	
6,816,741 B2	11/2004	Diab	
6,822,564 B2	11/2004	Al-Ali	
6,826,419 B2	11/2004	Diab et al.	
6,826,426 B2 *	11/2004	Lange	A61B 5/0478 600/300
6,830,711 B2	12/2004	Mills et al.	
6,847,899 B2 *	1/2005	Allgeyer	A61B 5/0059 702/188
6,850,787 B2	2/2005	Weber et al.	
6,850,788 B2	2/2005	Al-Ali	
6,852,083 B2	2/2005	Caro et al.	
6,861,639 B2	3/2005	Al-Ali	
6,898,452 B2	5/2005	Al-Ali et al.	
6,920,345 B2	7/2005	Al-Ali et al.	
6,931,268 B1	8/2005	Kiani-Azarbayjany et al.	
6,934,570 B2	8/2005	Kiani et al.	
6,939,305 B2	9/2005	Flaherty et al.	
6,943,348 B1	9/2005	Coffin, IV	
6,950,687 B2	9/2005	Al-Ali	
6,961,598 B2	11/2005	Diab	
6,970,792 B1	11/2005	Diab	
6,979,812 B2	12/2005	Al-Ali	
6,985,764 B2	1/2006	Mason et al.	
6,987,994 B1 *	1/2006	Mortz	A61B 5/14551 600/336
6,993,371 B2	1/2006	Kiani et al.	
6,996,427 B2	2/2006	Ali et al.	
6,999,904 B2	2/2006	Weber et al.	
7,003,338 B2	2/2006	Weber et al.	
7,003,339 B2	2/2006	Diab et al.	
7,015,451 B2	2/2006	Dalke et al.	
7,024,233 B2	4/2006	Ali et al.	
7,027,849 B2	4/2006	Al-Ali	
7,030,749 B2	4/2006	Al-Ali	
7,039,449 B2	5/2006	Al-Ali	
7,041,060 B2	5/2006	Flaherty et al.	
7,044,918 B2	5/2006	Diab	
7,067,893 B2	6/2006	Mills et al.	
7,081,095 B2 *	7/2006	Lynn	A61B 5/087 128/203.23
7,096,052 B2	8/2006	Mason et al.	
7,096,054 B2	8/2006	Abdul-Hafiz et al.	
7,132,641 B2	11/2006	Schulz et al.	
7,142,901 B2	11/2006	Kiani et al.	
7,149,561 B2	12/2006	Diab	
7,186,966 B2	3/2007	Al-Ali	
7,190,261 B2	3/2007	Al-Ali	
7,215,984 B2	5/2007	Diab	
7,215,986 B2	5/2007	Diab	
7,221,971 B2	5/2007	Diab	
7,225,006 B2	5/2007	Al-Ali et al.	
7,225,007 B2	5/2007	Al-Ali	
RE39,672 E	6/2007	Shehada et al.	
7,239,905 B2	7/2007	Kiani-Azarbayjany et al.	
7,245,953 B1	7/2007	Parker	
7,254,429 B2	8/2007	Schurman et al.	
7,254,431 B2	8/2007	Al-Ali	
7,254,433 B2	8/2007	Diab et al.	
7,254,434 B2	8/2007	Schulz et al.	
7,272,425 B2	9/2007	Al-Ali	
7,274,955 B2	9/2007	Kiani et al.	
D554,263 S	10/2007	Al-Ali	
7,280,858 B2	10/2007	Al-Ali et al.	
7,289,835 B2	10/2007	Mansfield et al.	
7,292,883 B2	11/2007	De Felice et al.	
7,295,866 B2	11/2007	Al-Ali	
7,316,231 B2 *	1/2008	Hickle	A61B 5/411 128/203.13
7,328,053 B1	2/2008	Diab et al.	
7,332,784 B2	2/2008	Mills et al.	
7,340,287 B2	3/2008	Mason et al.	
7,341,559 B2	3/2008	Schulz et al.	
7,343,186 B2	3/2008	Lamego et al.	
D566,282 S	4/2008	Al-Ali et al.	
7,355,512 B1	4/2008	Al-Ali	
7,356,365 B2	4/2008	Schurman	
7,371,981 B2	5/2008	Abdul-Hafiz	
7,373,193 B2	5/2008	Al-Ali et al.	
7,373,194 B2	5/2008	Weber et al.	
7,376,453 B1	5/2008	Diab et al.	
7,377,794 B2	5/2008	Al Ali et al.	
7,377,899 B2	5/2008	Weber et al.	
7,383,070 B2	6/2008	Diab et al.	
7,407,485 B2 *	8/2008	Huiku	A61B 5/0456 600/300
7,415,297 B2 *	8/2008	Al-Ali	A61B 5/14551 340/511
7,428,432 B2	9/2008	Ali et al.	
7,438,683 B2	10/2008	Al-Ali et al.	
7,440,787 B2	10/2008	Diab	
7,454,240 B2	11/2008	Diab et al.	
7,467,002 B2	12/2008	Weber et al.	
7,469,157 B2	12/2008	Diab et al.	
7,471,969 B2 *	12/2008	Diab	A61B 5/14551 600/323
7,471,971 B2	12/2008	Diab et al.	
7,483,729 B2	1/2009	Al-Ali et al.	
7,483,730 B2	1/2009	Diab et al.	
7,489,958 B2	2/2009	Diab et al.	
7,496,391 B2	2/2009	Diab et al.	
7,496,393 B2	2/2009	Diab et al.	
D587,657 S	3/2009	Al-Ali et al.	
7,499,741 B2	3/2009	Diab et al.	
7,499,835 B2	3/2009	Weber et al.	
7,500,950 B2	3/2009	Al-Ali et al.	
7,509,154 B2	3/2009	Diab et al.	
7,509,494 B2	3/2009	Al-Ali	
7,510,849 B2	3/2009	Schurman et al.	
7,526,328 B2	4/2009	Diab et al.	
7,530,942 B1	5/2009	Diab	
7,530,949 B2	5/2009	Al Ali et al.	
7,530,955 B2	5/2009	Diab et al.	
7,563,110 B2	7/2009	Al-Ali et al.	
7,596,398 B2	9/2009	Al-Ali et al.	
7,618,375 B2	11/2009	Flaherty	
D606,659 S	12/2009	Kiani et al.	
7,647,083 B2	1/2010	Al-Ali et al.	
D609,193 S	2/2010	Al-Ali et al.	
D614,305 S	4/2010	Al-Ali et al.	
RE41,317 E	5/2010	Parker	
7,729,733 B2	6/2010	Al-Ali et al.	
7,734,320 B2	6/2010	Al-Ali	
7,761,127 B2	7/2010	Al-Ali et al.	
7,761,128 B2	7/2010	Al-Ali et al.	
7,764,982 B2	7/2010	Dalke et al.	
D621,516 S	8/2010	Kiani et al.	
7,791,155 B2	9/2010	Diab	
7,801,581 B2	9/2010	Diab	
7,822,452 B2	10/2010	Schurman et al.	
RE41,912 E	11/2010	Parker	
7,844,313 B2	11/2010	Kiani et al.	
7,844,314 B2	11/2010	Al-Ali	
7,844,315 B2	11/2010	Al-Ali	
7,865,222 B2	1/2011	Weber et al.	
7,873,497 B2	1/2011	Weber et al.	
7,880,606 B2	2/2011	Al-Ali	
7,880,626 B2	2/2011	Al-Ali et al.	
7,891,355 B2	2/2011	Al-Ali et al.	
7,894,868 B2	2/2011	Al-Ali et al.	
7,899,507 B2	3/2011	Al-Ali et al.	
7,899,518 B2	3/2011	Trepagnier et al.	

(56)

References Cited

U.S. PATENT DOCUMENTS

7,904,132 B2	3/2011	Weber et al.	8,418,524 B2	4/2013	Al-Ali
7,909,772 B2	3/2011	Popov et al.	8,423,106 B2	4/2013	Lamego et al.
7,910,875 B2	3/2011	Al-Ali	8,428,967 B2	4/2013	Olsen et al.
7,919,713 B2	4/2011	Al-Ali et al.	8,430,817 B1	4/2013	Al-Ali et al.
7,937,128 B2	5/2011	Al-Ali	8,437,825 B2	5/2013	Dalvi et al.
7,937,129 B2	5/2011	Mason et al.	8,455,290 B2	6/2013	Siskavich
7,937,130 B2	5/2011	Diab et al.	8,457,703 B2	6/2013	Al-Ali
7,941,199 B2	5/2011	Kiani	8,457,707 B2	6/2013	Kiani
7,951,086 B2	5/2011	Flaherty et al.	8,463,349 B2	6/2013	Diab et al.
7,957,780 B2	6/2011	Lamego et al.	8,466,286 B2	6/2013	Bellot et al.
7,962,188 B2	6/2011	Kiani et al.	8,471,713 B2	6/2013	Poeze et al.
7,962,190 B1	6/2011	Diab et al.	8,473,020 B2	6/2013	Kiani et al.
7,976,472 B2	7/2011	Kiani	8,483,787 B2	7/2013	Al-Ali et al.
7,988,637 B2	8/2011	Diab	8,489,364 B2	7/2013	Weber et al.
7,990,382 B2	8/2011	Kiani	8,498,684 B2	7/2013	Weber et al.
7,991,446 B2	8/2011	Al-Ali et al.	8,509,867 B2	8/2013	Workman et al.
8,000,761 B2	8/2011	Al-Ali	8,515,509 B2	8/2013	Bruinsma et al.
8,008,088 B2	8/2011	Bellott et al.	8,523,781 B2	9/2013	Al-Ali
RE42,753 E	9/2011	Kiani-Azarbayjany et al.	8,529,301 B2	9/2013	Al-Ali et al.
8,019,400 B2	9/2011	Diab et al.	8,532,727 B2	9/2013	Ali et al.
8,028,701 B2	10/2011	Al-Ali et al.	8,532,728 B2	9/2013	Diab et al.
8,029,765 B2	10/2011	Bellott et al.	D692,145 S	10/2013	Al-Ali et al.
8,036,728 B2	10/2011	Diab et al.	8,547,209 B2	10/2013	Kiani et al.
8,046,040 B2	10/2011	Ali et al.	8,548,548 B2	10/2013	Al-Ali
8,046,041 B2	10/2011	Diab et al.	8,548,550 B2	10/2013	Al-Ali et al.
8,046,042 B2	10/2011	Diab et al.	8,560,032 B2	10/2013	Al-Ali et al.
8,048,040 B2	11/2011	Kiani	8,560,034 B1	10/2013	Diab et al.
8,050,728 B2	11/2011	Al-Ali et al.	8,570,167 B2	10/2013	Al-Ali
RE43,169 E	2/2012	Parker	8,570,503 B2	10/2013	Vo et al.
8,118,620 B2	2/2012	Al-Ali et al.	8,571,618 B1	10/2013	Lamego et al.
8,126,528 B2	2/2012	Diab et al.	8,571,619 B2	10/2013	Al-Ali et al.
8,128,572 B2	3/2012	Diab et al.	8,584,345 B2	10/2013	Al-Ali et al.
8,130,105 B2	3/2012	Al-Ali et al.	8,577,431 B2	11/2013	Lamego et al.
8,145,287 B2	3/2012	Diab et al.	8,588,880 B2	11/2013	Abdul-Hafiz et al.
8,150,487 B2	4/2012	Diab et al.	8,600,467 B2	12/2013	Al-Ali et al.
8,175,672 B2	5/2012	Parker	8,606,342 B2	12/2013	Diab
8,180,420 B2	5/2012	Diab et al.	8,626,255 B2	1/2014	Al-Ali et al.
8,182,443 B1 *	5/2012	Kiani A61M 16/12 604/131	8,630,691 B2	1/2014	Lamego et al.
8,185,180 B2	5/2012	Diab et al.	8,634,889 B2	1/2014	Al-Ali et al.
8,190,223 B2	5/2012	Al-Ali et al.	8,641,631 B2	2/2014	Sierra et al.
8,190,227 B2	5/2012	Diab et al.	8,652,060 B2	2/2014	Al-Ali
8,203,438 B2	6/2012	Kiani et al.	8,663,107 B2	3/2014	Kiani
8,203,704 B2	6/2012	Merritt et al.	8,666,468 B1	3/2014	Al-Ali
8,224,411 B2	7/2012	Al-Ali et al.	8,667,967 B2	3/2014	Al-Ali et al.
8,228,181 B2	7/2012	Al-Ali	8,670,811 B2	3/2014	O'Reilly
8,229,533 B2	7/2012	Diab et al.	8,670,814 B2	3/2014	Diab et al.
8,233,955 B2	7/2012	Al-Ali et al.	8,676,286 B2	3/2014	Weber et al.
8,244,325 B2	8/2012	Al-Ali et al.	8,682,407 B2	3/2014	Al-Ali
8,255,026 B1	8/2012	Al-Ali	RE44,823 E	4/2014	Parker
8,255,027 B2	8/2012	Al-Ali et al.	RE44,875 E	4/2014	Kiani et al.
8,255,028 B2	8/2012	Al-Ali et al.	8,690,799 B2	4/2014	Telfort et al.
8,260,577 B2	9/2012	Weber et al.	8,700,112 B2	4/2014	Kiani
8,265,723 B1	9/2012	McHale et al.	8,702,627 B2	4/2014	Telfort et al.
8,274,360 B2	9/2012	Sampath et al.	8,706,179 B2	4/2014	Parker
8,301,217 B2	10/2012	Al-Ali et al.	8,712,494 B1	4/2014	MacNeish, III et al.
8,310,336 B2	11/2012	Muhsin et al.	8,715,206 B2	5/2014	Telfort et al.
8,315,683 B2	11/2012	Al-Ali et al.	8,718,735 B2	5/2014	Lamego et al.
RE43,860 E	12/2012	Parker	8,718,737 B2	5/2014	Diab et al.
8,337,403 B2	12/2012	Al-Ali et al.	8,718,738 B2	5/2014	Blank et al.
8,346,330 B2	1/2013	Lamego	8,720,249 B2	5/2014	Al-Ali
8,353,842 B2	1/2013	Al-Ali et al.	8,721,541 B2	5/2014	Al-Ali et al.
8,355,766 B2	1/2013	MacNeish, III et al.	8,721,542 B2 *	5/2014	Al-Ali A61B 5/14551 600/301
8,359,080 B2	1/2013	Diab et al.	8,723,677 B1	5/2014	Kiani
8,364,223 B2	1/2013	Al-Ali et al.	8,740,792 B1	6/2014	Kiani et al.
8,364,226 B2	1/2013	Diab et al.	8,754,776 B2	6/2014	Poeze et al.
8,374,665 B2	2/2013	Lamego	8,755,535 B2	6/2014	Telfort et al.
8,385,995 B2	2/2013	Al-Ali et al.	8,755,856 B2	6/2014	Diab et al.
8,385,996 B2	2/2013	Smith et al.	8,755,872 B1	6/2014	Marinow
8,388,353 B2	3/2013	Kiani et al.	8,761,850 B2	6/2014	Lamego
8,399,822 B2	3/2013	Al-Ali	8,764,671 B2	7/2014	Kiani
8,401,602 B2	3/2013	Kiani	8,768,423 B2	7/2014	Shakespeare et al.
8,401,607 B2	3/2013	Mannheimer	8,771,204 B2	7/2014	Telfort et al.
8,405,608 B2	3/2013	Al-Ali et al.	8,777,634 B2	7/2014	Kiani et al.
8,414,499 B2	4/2013	Al-Ali et al.	8,781,543 B2	7/2014	Diab et al.
			8,781,544 B2	7/2014	Al-Ali et al.
			8,781,549 B2	7/2014	Al-Ali et al.
			8,788,003 B2	7/2014	Schurman et al.
			8,790,268 B2	7/2014	Al-Ali

(56)

References Cited

U.S. PATENT DOCUMENTS

8,801,613 B2	8/2014	Al-Ali et al.	9,245,668 B1	1/2016	Vo et al.
8,821,397 B2	9/2014	Al-Ali et al.	9,259,185 B2	2/2016	Abdul-Hafiz et al.
8,821,415 B2	9/2014	Al-Ali et al.	9,267,572 B2	2/2016	Barker et al.
8,830,449 B1	9/2014	Lamego et al.	9,277,880 B2	3/2016	Poeze et al.
8,831,700 B2	9/2014	Schurman et al.	9,289,167 B2	3/2016	Diab et al.
8,840,549 B2	9/2014	Al-Ali et al.	9,295,421 B2	3/2016	Kiani et al.
8,847,740 B2	9/2014	Kiani et al.	9,307,928 B1	4/2016	Al-Ali et al.
8,849,365 B2	9/2014	Smith et al.	9,323,894 B2	4/2016	Kiani
8,852,094 B2 *	10/2014	Al-Ali A61B 5/0205	D755,392 S	5/2016	Hwang et al.
		128/898	9,326,712 B1	5/2016	Kiani
8,852,994 B2	10/2014	Wojtczuk et al.	9,333,316 B2	5/2016	Kiani
8,868,147 B2	10/2014	Stippick et al.	9,339,220 B2	5/2016	Lamego et al.
8,868,150 B2	10/2014	Al-Ali et al.	9,341,565 B2	5/2016	Lamego et al.
8,870,792 B2	10/2014	Al-Ali et al.	9,351,673 B2	5/2016	Diab et al.
8,886,271 B2	11/2014	Kiani et al.	9,351,675 B2	5/2016	Al-Ali et al.
8,888,539 B2	11/2014	Al-Ali et al.	9,364,181 B2	6/2016	Kiani et al.
8,888,708 B2	11/2014	Diab et al.	9,368,671 B2	6/2016	Wojtczuk et al.
8,892,180 B2	11/2014	Weber et al.	9,370,325 B2	6/2016	Al-Ali et al.
8,897,847 B2	11/2014	Al-Ali	9,370,326 B2	6/2016	McHale et al.
8,909,310 B2	12/2014	Lamego et al.	9,370,335 B2	6/2016	Al-Ali et al.
8,911,377 B2	12/2014	Al-Ali	9,375,185 B2	6/2016	Ali et al.
8,912,909 B2	12/2014	Al-Ali et al.	9,386,953 B2	7/2016	Al-Ali
8,920,317 B2	12/2014	Al-Ali et al.	9,386,961 B2	7/2016	Al-Ali et al.
8,921,699 B2	12/2014	Al-Ali et al.	9,392,945 B2	7/2016	Al-Ali et al.
8,922,382 B2	12/2014	Al-Ali et al.	9,397,448 B2	7/2016	Al-Ali et al.
8,929,964 B2	1/2015	Al-Ali et al.	9,408,542 B1	8/2016	Kinast et al.
8,932,227 B2 *	1/2015	Lynn A61B 5/00	9,436,645 B2	9/2016	Al-Ali et al.
		600/484	9,445,759 B1	9/2016	Lamego et al.
8,942,777 B2	1/2015	Diab et al.	9,466,919 B2	10/2016	Kiani et al.
8,948,834 B2	2/2015	Diab et al.	9,474,474 B2	10/2016	Lamego et al.
8,948,835 B2	2/2015	Diab	9,480,422 B2	11/2016	Al-Ali
8,965,471 B2	2/2015	Lamego	9,480,435 B2	11/2016	Olsen
8,983,564 B2	3/2015	Al-Ali	9,492,110 B2	11/2016	Al-Ali et al.
8,989,831 B2	3/2015	Al-Ali et al.	9,510,779 B2	12/2016	Poeze et al.
8,996,085 B2	3/2015	Kiani et al.	9,517,024 B2 *	12/2016	Kiani A61B 5/0205
8,998,809 B2	4/2015	Kiani	9,532,722 B2	1/2017	Lamego et al.
9,028,429 B2	5/2015	Telfort et al.	9,538,949 B2	1/2017	Al-Ali et al.
9,037,207 B2	5/2015	Al-Ali et al.	9,538,980 B2	1/2017	Telfort et al.
9,060,721 B2	6/2015	Reichgott et al.	9,549,696 B2	1/2017	Lamego et al.
9,066,666 B2	6/2015	Kiani	9,554,737 B2	1/2017	Schurman et al.
9,066,680 B1	6/2015	Al-Ali et al.	9,560,996 B2	2/2017	Kiani
9,072,474 B2	7/2015	Al-Ali et al.	9,560,998 B2	2/2017	Al-Ali et al.
9,078,560 B2	7/2015	Schurman et al.	9,566,019 B2	2/2017	Al-Ali et al.
9,084,569 B2	7/2015	Weber et al.	9,579,039 B2	2/2017	Jansen et al.
9,095,316 B2	8/2015	Welch et al.	9,591,975 B2	3/2017	Dalvi et al.
9,106,038 B2 *	8/2015	Telfort A61B 5/04282	9,622,692 B2	4/2017	Lamego et al.
9,107,625 B2	8/2015	Telfort et al.	9,622,693 B2	4/2017	Diab
9,107,626 B2	8/2015	Al-Ali et al.	D788,312 S	5/2017	Al-Ali et al.
9,113,831 B2	8/2015	Al-Ali	9,636,055 B2	5/2017	Al-Ali et al.
9,113,832 B2	8/2015	Al-Ali	9,636,056 B2	5/2017	Al-Ali
9,119,595 B2	9/2015	Lamego	9,649,054 B2	5/2017	Lamego et al.
9,131,881 B2	9/2015	Diab et al.	9,662,052 B2	5/2017	Al-Ali et al.
9,131,882 B2	9/2015	Al-Ali et al.	9,668,679 B2	6/2017	Schurman et al.
9,131,883 B2	9/2015	Al-Ali	9,668,680 B2	6/2017	Bruinsma et al.
9,131,917 B2	9/2015	Telfort et al.	9,668,703 B2	6/2017	Al-Ali
9,138,180 B1	9/2015	Coverston et al.	9,675,286 B2	6/2017	Diab
9,138,182 B2	9/2015	Al-Ali et al.	9,687,160 B2	6/2017	Kiani
9,138,192 B2	9/2015	Weber et al.	9,693,719 B2	7/2017	Al-Ali et al.
9,142,117 B2	9/2015	Muhsin et al.	9,693,737 B2	7/2017	Al-Ali
9,153,112 B1	10/2015	Kiani et al.	9,697,928 B2	7/2017	Al-Ali et al.
9,153,121 B2	10/2015	Kiani et al.	9,717,425 B2	8/2017	Kiani et al.
9,161,696 B2	10/2015	Al-Ali et al.	9,717,458 B2	8/2017	Lamego et al.
9,161,713 B2	10/2015	Al-Ali et al.	9,724,016 B1	8/2017	Al-Ali et al.
9,167,995 B2	10/2015	Lamego et al.	9,724,024 B2	8/2017	Al-Ali
9,176,141 B2	11/2015	Al-Ali et al.	9,724,025 B1	8/2017	Kiani et al.
9,186,102 B2	11/2015	Bruinsma et al.	9,743,887 B2	8/2017	Al-Ali et al.
9,192,312 B2	11/2015	Al-Ali	9,749,232 B2	8/2017	Sampath et al.
9,192,329 B2	11/2015	Al-Ali	9,750,442 B2	9/2017	Olsen
9,192,351 B1	11/2015	Telfort et al.	9,750,461 B1	9/2017	Telfort
9,195,385 B2	11/2015	Al-Ali et al.	2002/0107434 A1 *	8/2002	Lange A61B 5/0478
9,211,072 B2	12/2015	Kiani			600/301
9,211,095 B1	12/2015	Al-Ali	2002/0111754 A1 *	8/2002	Lange A61B 5/0478
9,218,454 B2	12/2015	Kiani et al.			702/57
9,226,696 B2	1/2016	Kiani	2002/0190863 A1	12/2002	Lynn
9,241,662 B2	1/2016	Al-Ali et al.	2003/0000522 A1 *	1/2003	Lynn A61B 5/087
					128/200.24
			2003/0106553 A1 *	6/2003	Vanderveen A61M 5/1723
					128/204.18
			2003/0158466 A1	8/2003	Lynn et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2004/0111014	A1	6/2004	Hickle		
2004/0127792	A1	7/2004	Siejko et al.		
2004/0193068	A1 *	9/2004	Burton	A61B 5/0476	
				600/544	
2005/0177096	A1 *	8/2005	Bollish	A61B 5/02055	
				604/65	
2005/0203352	A1 *	9/2005	Al-Ali	A61B 5/14551	
				600/309	
2007/0129647	A1 *	6/2007	Lynn	A61B 5/00	
				600/538	
2007/0191697	A1 *	8/2007	Lynn	A61B 5/0205	
				600/323	
2007/0282478	A1	12/2007	Al-Ali et al.		
2007/0299389	A1 *	12/2007	Halbert	A61B 5/0205	
				604/65	
2008/0300471	A1 *	12/2008	Al-Ali	A61B 5/14551	
				600/301	
2009/0247984	A1	10/2009	Lamego et al.		
2009/0275813	A1	11/2009	Davis		
2009/0275844	A1	11/2009	Al-Ali		
2010/0004518	A1	1/2010	Vo et al.		
2010/0030040	A1	2/2010	Poeze et al.		
2011/0082711	A1	4/2011	Poeze et al.		
2011/0087083	A1	4/2011	Poeze et al.		
2011/0105854	A1	5/2011	Kiani et al.		
2011/0125060	A1	5/2011	Telfort et al.		
2011/0208015	A1	8/2011	Welch et al.		
2011/0213212	A1	9/2011	Al-Ali		
2011/0230733	A1	9/2011	Al-Ali		
2011/0237969	A1	9/2011	Eckerbom et al.		
2011/0288383	A1	11/2011	Diab		
2011/0301444	A1	12/2011	Al-Ali		
2012/0041316	A1	2/2012	Al-Ali et al.		
2012/0046557	A1	2/2012	Kiani		
2012/0059267	A1	3/2012	Lamego et al.		
2012/0088984	A1	4/2012	Al-Ali et al.		
2012/0165629	A1	6/2012	Merritt et al.		
2012/0179006	A1	7/2012	Jansen et al.		
2012/0209082	A1	8/2012	Al-Ali		
2012/0209084	A1	8/2012	Olsen et al.		
2012/0283524	A1	11/2012	Kiani et al.		
2012/0296178	A1	11/2012	Lamego et al.		
2012/0319816	A1	12/2012	Al-Ali		
2012/0330112	A1	12/2012	Lamego et al.		
2013/0023775	A1	1/2013	Lamego et al.		
2013/0041591	A1	2/2013	Lamego		
2013/0046204	A1	2/2013	Lamego et al.		
2013/0060147	A1	3/2013	Welch et al.		
2013/0096405	A1	4/2013	Garfio		
2013/0096936	A1	4/2013	Sampath et al.		
2013/0190581	A1	7/2013	Al-Ali et al.		
2013/0211214	A1	8/2013	Olsen		
2013/0243021	A1	9/2013	Siskavich		
2013/0253334	A1	9/2013	Al-Ali et al.		
2013/0262730	A1	10/2013	Al-Ali et al.		
2013/0267804	A1	10/2013	Al-Ali		
2013/0274572	A1	10/2013	Al-Ali et al.		
2013/0296672	A1	11/2013	O'Neil et al.		
2013/0296713	A1	11/2013	Al-Ali et al.		
2013/0317370	A1	11/2013	Dalvi et al.		
2013/0324808	A1	12/2013	Al-Ali et al.		
2013/0331660	A1	12/2013	Al-Ali et al.		
2013/0331670	A1	12/2013	Kiani		
2014/0012100	A1	1/2014	Al-Ali et al.		
2014/0034353	A1	2/2014	Al-Ali et al.		
2014/0051953	A1	2/2014	Lamego et al.		
2014/0066783	A1	3/2014	Kiani et al.		
2014/0077956	A1	3/2014	Sampath et al.		
2014/0081100	A1 *	3/2014	Muhsin	A61B 5/0002	
				600/324	
2014/0081175	A1	3/2014	Telfort		
2014/0094667	A1	4/2014	Schurman et al.		
2014/0100434	A1	4/2014	Diab et al.		
2014/0114199	A1	4/2014	Lamego et al.		
2014/0120564	A1	5/2014	Workman et al.		
2014/0121482	A1	5/2014	Merritt et al.		
2014/0121483	A1	5/2014	Kiani		
2014/0127137	A1	5/2014	Bellott et al.		
2014/0129702	A1	5/2014	Lamego et al.		
2014/0135588	A1	5/2014	Al-Ali et al.		
2014/0142401	A1	5/2014	Al-Ali et al.		
2014/0163344	A1	6/2014	Al-Ali		
2014/0163402	A1	6/2014	Lamego et al.		
2014/0166076	A1	6/2014	Kiani et al.		
2014/0171763	A1	6/2014	Diab		
2014/0180038	A1	6/2014	Kiani		
2014/0180154	A1	6/2014	Sierra et al.		
2014/0180160	A1	6/2014	Brown et al.		
2014/0187973	A1	7/2014	Brown et al.		
2014/0194766	A1	7/2014	Al-Ali et al.		
2014/0206963	A1	7/2014	Al-Ali		
2014/0213864	A1	7/2014	Abdul-Hafiz et al.		
2014/0266790	A1	9/2014	Al-Ali et al.		
2014/0275808	A1	9/2014	Poeze et al.		
2014/0275835	A1	9/2014	Lamego et al.		
2014/0275871	A1	9/2014	Lamego et al.		
2014/0275872	A1	9/2014	Merritt et al.		
2014/0275881	A1	9/2014	Lamego et al.		
2014/0276115	A1	9/2014	Dalvi et al.		
2014/0288400	A1	9/2014	Diab et al.		
2014/0303520	A1	10/2014	Telfort et al.		
2014/0316217	A1 *	10/2014	Purdon	A61B 5/4821	
				600/301	
2014/0316218	A1	10/2014	Purdon et al.		
2014/0316228	A1	10/2014	Blank et al.		
2014/0323825	A1	10/2014	Al-Ali et al.		
2014/0323897	A1	10/2014	Brown et al.		
2014/0323898	A1 *	10/2014	Purdon	A61B 5/4821	
				600/544	
2014/0330092	A1 *	11/2014	Al-Ali	A61B 5/14551	
				600/301	
2014/0330098	A1	11/2014	Merritt et al.		
2014/0330099	A1	11/2014	Al-Ali et al.		
2014/0336481	A1	11/2014	Shakespeare et al.		
2014/0357966	A1	12/2014	Al-Ali et al.		
2014/0371548	A1	12/2014	Al-Ali et al.		
2014/0371632	A1	12/2014	Al-Ali et al.		
2014/0378784	A1	12/2014	Kiani et al.		
2015/0005600	A1	1/2015	Blank et al.		
2015/0011907	A1	1/2015	Purdon et al.		
2015/0012231	A1	1/2015	Poeze et al.		
2015/0018650	A1	1/2015	Al-Ali et al.		
2015/0025406	A1	1/2015	Al-Ali		
2015/0032029	A1	1/2015	Al-Ali et al.		
2015/0038859	A1	2/2015	Dalvi et al.		
2015/0045637	A1	2/2015	Dalvi		
2015/0051462	A1	2/2015	Olsen		
2015/0080754	A1	3/2015	Purdon et al.		
2015/0087936	A1	3/2015	Al-Ali et al.		
2015/0094546	A1	4/2015	Al-Ali		
2015/0097701	A1	4/2015	Al-Ali et al.		
2015/0099950	A1	4/2015	Al-Ali et al.		
2015/0099951	A1	4/2015	Al-Ali et al.		
2015/0099955	A1	4/2015	Al-Ali et al.		
2015/0101844	A1	4/2015	Al-Ali et al.		
2015/0106121	A1	4/2015	Muhsin et al.		
2015/0112151	A1	4/2015	Muhsin et al.		
2015/0116076	A1	4/2015	Al-Ali et al.		
2015/0126830	A1	5/2015	Schurman et al.		
2015/0133755	A1	5/2015	Smith et al.		
2015/0137988	A1 *	5/2015	Gravenstein	A61B 5/002	
				340/870.02	
2015/0140863	A1	5/2015	Al-Ali et al.		
2015/0141781	A1	5/2015	Weber et al.		
2015/0165312	A1	6/2015	Kiani		
2015/0196237	A1	7/2015	Lamego		
2015/0201874	A1	7/2015	Diab		
2015/0208966	A1	7/2015	Al-Ali		
2015/0216459	A1	8/2015	Al-Ali et al.		
2015/0230755	A1	8/2015	Al-Ali et al.		
2015/0238722	A1	8/2015	Al-Ali		
2015/0245773	A1	9/2015	Lamego et al.		
2015/0245794	A1	9/2015	Al-Ali		

(56)

References Cited

U.S. PATENT DOCUMENTS

2015/0257689 A1 9/2015 Al-Ali et al.
 2015/0272514 A1 10/2015 Kiani et al.
 2015/0351697 A1 12/2015 Weber et al.
 2015/0351704 A1 12/2015 Kiani et al.
 2015/0359429 A1 12/2015 Al-Ali et al.
 2015/0366472 A1 12/2015 Kiani
 2015/0366507 A1 12/2015 Blank
 2015/0374298 A1 12/2015 Al-Ali et al.
 2015/0380875 A1 12/2015 Coverston et al.
 2016/0000362 A1 1/2016 Diab et al.
 2016/0007930 A1 1/2016 Weber et al.
 2016/0029932 A1 2/2016 Al-Ali
 2016/0029933 A1 2/2016 Al-Ali et al.
 2016/0045118 A1 2/2016 Kiani
 2016/0051205 A1 2/2016 Al-Ali et al.
 2016/0058338 A1 3/2016 Schurman et al.
 2016/0058347 A1 3/2016 Reichgott et al.
 2016/0066823 A1 3/2016 Kind et al.
 2016/0066824 A1 3/2016 Al-Ali et al.
 2016/0066879 A1 3/2016 Telfort et al.
 2016/0072429 A1 3/2016 Kiani et al.
 2016/0073967 A1 3/2016 Lamego et al.
 2016/0081552 A1 3/2016 Wojtczuk et al.
 2016/0095543 A1 4/2016 Telfort et al.
 2016/0095548 A1 4/2016 Al-Ali et al.
 2016/0103598 A1 4/2016 Al-Ali et al.
 2016/0113527 A1 4/2016 Al-Ali et al.
 2016/0143548 A1 5/2016 Al-Ali
 2016/0166182 A1 6/2016 Al-Ali et al.
 2016/0166183 A1 6/2016 Poeze et al.
 2016/0166210 A1 6/2016 Al-Ali
 2016/0192869 A1 7/2016 Kiani et al.
 2016/0196388 A1 7/2016 Lamego
 2016/0197436 A1 7/2016 Barker et al.
 2016/0213281 A1 7/2016 Eckerbom et al.
 2016/0228043 A1 8/2016 O'Neil et al.
 2016/0233632 A1 8/2016 Scruggs et al.
 2016/0234944 A1 8/2016 Schmidt et al.
 2016/0270735 A1 9/2016 Diab et al.
 2016/0283665 A1 9/2016 Sampath et al.
 2016/0287090 A1 10/2016 Al-Ali et al.
 2016/0287786 A1 10/2016 Kiani
 2016/0296169 A1 10/2016 McHale et al.
 2016/0310052 A1 10/2016 Al-Ali et al.
 2016/0314260 A1 10/2016 Kiani
 2016/0324486 A1 11/2016 Al-Ali et al.
 2016/0324488 A1 11/2016 Olsen
 2016/0327984 A1 11/2016 Al-Ali et al.
 2016/0328528 A1 11/2016 Al-Ali et al.
 2016/0331332 A1 11/2016 Al-Ali

2016/0367173 A1 12/2016 Dalvi et al.
 2017/0000394 A1 1/2017 Al-Ali et al.
 2017/0007134 A1 1/2017 Al-Ali et al.
 2017/0007190 A1 1/2017 Al-Ali et al.
 2017/0007198 A1 1/2017 Al-Ali et al.
 2017/0014083 A1 1/2017 Diab et al.
 2017/0014084 A1 1/2017 Al-Ali et al.
 2017/0021099 A1 1/2017 Al-Ali et al.
 2017/0027456 A1 2/2017 Kinast et al.
 2017/0042488 A1 2/2017 Muhsin
 2017/0055847 A1 3/2017 Kiani et al.
 2017/0055851 A1 3/2017 Al-Ali
 2017/0055882 A1 3/2017 Al-Ali et al.
 2017/0055887 A1 3/2017 Al-Ali
 2017/0055896 A1 3/2017 Al-Ali et al.
 2017/0079594 A1 3/2017 Telfort et al.
 2017/0086723 A1 3/2017 Al-Ali et al.
 2017/0143281 A1 5/2017 Olsen
 2017/0147774 A1 5/2017 Kiani
 2017/0156620 A1 6/2017 Al-Ali et al.
 2017/0173632 A1 6/2017 Al-Ali
 2017/0187146 A1 6/2017 Kiani et al.
 2017/0188919 A1 7/2017 Al-Ali et al.
 2017/0196464 A1 7/2017 Jansen et al.
 2017/0196470 A1 7/2017 Lamego et al.
 2017/0202490 A1 7/2017 Al-Ali et al.
 2017/0224216 A1 8/2017 Al-Ali
 2017/0224231 A1 8/2017 Al-Ali
 2017/0224233 A1 8/2017 Al-Ali
 2017/0224262 A1 8/2017 Al-Ali
 2017/0231537 A1 8/2017 Al-Ali
 2017/0245790 A1 8/2017 Al-Ali et al.
 2017/0251974 A1 9/2017 Shreim et al.
 2017/0251975 A1 9/2017 Shreim et al.
 2017/0258403 A1 9/2017 Abdul-Hafiz et al.
 2018/0125430 A1* 5/2018 Al-Ali A61B 5/0205

OTHER PUBLICATIONS

Bloom, Marc J., "Techniques to Identify Clinical Contexts During Automated Data Analysis", International Journal of Clinical Monitoring and Computing Netherlands, Feb. 1993, vol. 10, No. 1, pp. 17-22.

European Communication issued in EP Application No. 05 724 991.4, dated Jan. 13, 2009 in 5 pages.

EPO Examination Report, dated Sep. 29, 2010 re Application No. 05 724 991.4-1265.

Horn, Werner, et al. "Effective Data Validation of High-Frequency Data: Time-Point-, Time-Interval-, and Trend-Based Methods", Computers in Biology and Medicine, Sep. 1997, vol. 27, No. 5, pp. 389-409.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 7

PHYSIOLOGICAL PARAMETER SYSTEM**CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a divisional of U.S. patent application Ser. No. 12/188,154, titled Physiological Parameter System, filed Aug. 7, 2008, and U.S. patent application Ser. No. 11/075,389 (now U.S. Pat. No. 7,415,297), titled Physiological Parameter System, filed Mar. 8, 2005, which relates to and claims the benefit of U.S. Provisional Applications No. 60/551,165, titled Combined Physiological Parameter Monitor, filed Mar. 8, 2004 and No. 60/600,640, titled Physiological Parameter Controller, filed Aug. 11, 2004. Each of the foregoing applications are incorporated by reference herein.

BACKGROUND OF THE INVENTION

Pulse oximetry is a widely accepted noninvasive procedure for measuring the oxygen saturation level of arterial blood, an indicator of a person's oxygen supply. Early detection of a low blood oxygen level is critical in the medical field, for example in critical care and surgical applications, because an insufficient supply of oxygen can result in brain damage and death in a matter of minutes. A typical pulse oximetry system utilizes a sensor applied to a patient's finger. The sensor has an emitter configured with both red and infrared LEDs that project light through the finger to a detector so as to determine the ratio of oxygenated and deoxygenated hemoglobin light absorption. In particular, the detector generates first and second intensity signals responsive to the red and IR wavelengths emitted by the LEDs after absorption by constituents of pulsatile blood flowing within a fleshy medium, such as a finger tip. A pulse oximetry sensor is described in U.S. Pat. No. 6,088,607 titled Low Noise Optical Probe, which is assigned to Masimo Corporation, Irvine, Calif. and incorporated by reference herein.

Capnography comprises the continuous analysis and recording of carbon dioxide concentrations in the respiratory gases of patients. The device used to measure the CO₂ concentrations is referred to as a capnometer. CO₂ monitoring can be performed on both intubated and non-intubated patients. With non-intubated patients, a nasal cannula is used. Capnography helps to identify situations that can lead to hypoxia if uncorrected. Moreover, it also helps in the swift differential diagnosis of hypoxia before hypoxia can lead to irreversible brain damage. Pulse oximetry is a direct monitor of the oxygenation status of a patient. Capnography, on the other hand, is an indirect monitor that helps in the differential diagnosis of hypoxia so as to enable remedial measures to be taken expeditiously before hypoxia results in an irreversible brain damage.

SUMMARY OF THE INVENTION

Multiple physiological parameters, combined, provide a more powerful patient condition assessment tool than when any physiological parameter is used by itself. For example, a combination of parameters can provide greater confidence if an alarm condition is occurring. More importantly, such a combination can be used to give an early warning of a slowly deteriorating patient condition as compared to any single parameter threshold, which may not indicate such a condition for many minutes. Conditions such as hypovolemia, hypotension, and airway obstruction may develop

slowly over time. A physiological parameter system that combines multiple parameters so as to provide an early warning could have a major effect on the morbidity and mortality outcome in such cases.

Further, a greater emphasis has been put on decreasing the pain level of patients on the ward. Accordingly, patients are often given an IV setup that enables the patient to increase the level of analgesia at will. In certain situations, however, the patient's input must be ignored so as to avoid over medication. Complications from over sedation may include hypotension, tachycardia, bradycardia, hypoventilation and apnea. A physiological parameter system that uses pulse oximetry monitoring of SpO₂ and pulse rate in conjunction with patient controlled analgesia (PCA) can aid in patient safety. Utilization of conventional pulse oximetry in conjunction with PCA, however, can result in the patient being erroneously denied pain medication. Conventional monitors are susceptible to patient motion, which is likely to increase with rising pain. Further, conventional monitors do not provide an indication of output reliability.

Advanced pulse oximetry is motion tolerant and also provides one or more indications of signal quality of data confidence. These indicators can be used as arbitrators in decision algorithms for adjusting the PCA administration and sedation monitoring. Further, advanced pulse oximetry can provide parameters in addition to oxygen saturation and pulse rate, such as perfusion index (PI). For example hypotension can be assessed by changes in PI, which may be associated with changes in pulse rate. Motion tolerant pulse oximetry is described in U.S. Pat. No. 6,699,194 titled Signal Processing Apparatus and Method; signal quality and data confidence indicators are described in U.S. Pat. No. 6,684,090 titled Pulse Oximetry Data Confidence Indicator, both of which are assigned to Masimo Corporation, Irvine, Calif. and incorporated by reference herein.

One aspect of a physiological parameter system in a first parameter input responsive to a first physiological sensor and a second parameter input responsive to a second physiological sensor. A processor is adapted to combine the parameters and predetermined limits for the parameters so as to generate an alarm output.

Another aspect of a physiological parameter system is a parameter input responsive to a physiological sensor and a quality indicator input relating to confidence in the parameter input. A processor is adapted to combine the parameter input, the quality indicator input and predetermined limits for the parameter input and the quality indicator input so as to generate a control output.

A physiological parameter method comprises the steps of inputting a parameter responsive to a physiological sensor and inputting a quality indicator related to data confidence for the parameter. A control signal is output from the combination of the parameter and the quality indicator. The control signal is adapted to affect the operation of a medical-related device.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a general block diagram of a physiological parameter system having alarm, diagnostic and control outputs;

FIG. 2 is a block diagram of a physiological parameter system combining pulse oximetry and capnography and providing alarm outputs;

FIG. 3 is a block diagram of a saturation limit alarm enhanced by ETCO₂ measurements;

FIG. 4 is a block diagram of a CO₂ waveform alarm enhanced by SpO₂ measurements;

FIG. 5 is a block diagram of a physiological parameter system combining pulse oximetry and capnography and providing a diagnostic output; and

FIGS. 6A, 6B and 7 are block diagrams of a physiological parameter system utilizing pulse oximetry to control patient controlled analgesia (PCA).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

FIG. 1 illustrates a physiological parameter system 100, which may comprise an expert system, a neural-network or a logic circuit, for example. The physiological parameter system 100 has as inputs 101 one or more parameters from one or more physiological measurement devices, such as a pulse oximetry 110 and/or a capnometer 120. Pulse oximeter parameters may include oxygen saturation (SpO₂), perfusion index (PI), pulse rate (PR), various signal quality and/or data confidence indicators (Qn) and trend data, to name a few. Capnography parameter inputs may include, for example, an exhaled carbon dioxide waveform, end tidal carbon dioxide (ETCO₂) and respiration rate (RR). Signal quality and data confidence indicators are described in U.S. Pat. No. 6,684, 090 cited above. The physiological parameter system 100 may also have parameter limits 105, which may be user inputs, default conditions or otherwise predetermined thresholds within the system 100.

The inputs 101 are processed in combination to generate one or more outputs 102 comprising alarms, diagnostics and controls. Alarms may be used to alert medical personnel to a deteriorating condition in a patient under their care. Diagnostics may be used to assist medical personnel in determining a patient condition. Controls may be used to affect the operation of a medical-related device. Other measurement parameters 130 that can be input to the monitor may include or relate to one or more of ECG, blood glucose, blood pressure (BP), temperature (T), HbCO and MetHb, to name a few.

FIG. 2 illustrates one embodiment of a physiological parameter system 200 combining pulse oximetry parameter inputs 210 and capnography parameter inputs 220 so as to generate alarm outputs 202. Parameter limits 205 may be user inputs, default conditions or otherwise predetermined alarm thresholds for these parameters 210, 220. The alarms 202 are grouped as pulse oximetry related 230, capnography related 240 and a combination 250. For example, a pulse oximetry alarm 230 may be related to percent oxygen saturation and trigger when oxygen saturation falls below a predetermined percentage limit. A capnography alarm 240 may be related to ETCO₂ and trigger when ETCO₂ falls below or rises above a predetermined mm Hg pressure limit. A combination alarm 250 may indicate a particular medical condition related to both pulse oximetry and capnography or may indicate a malfunction in either instrument.

FIG. 3 illustrates a SpO₂ alarm embodiment 300 that is responsive to ETCO₂. In particular, a SpO₂ alarm 305 may be triggered sooner and may indicate a high priority if ETCO₂ 303 is falling. That is, if ETCO₂ 303 is trending down above a certain rate, the SpO₂ alarm 305 is triggered at a higher percentage oxygen saturation threshold and alerts a caregiver to the possibility of a serious condition, e.g., a pulmonary embolism.

As shown in FIG. 3, a slope detector 310 determines the slope 312 of the ETCO₂ input 303. A slope comparator 320 compares this slope 312 to a predetermined slope limit 304.

If the downward trend of ETCO₂ 303 is great enough, a delta value 303 is added 340 to the SpO₂ lower limit 302 to generate a variable threshold 342. A threshold comparator 350 compares this variable threshold 342 to the SpO₂ input 301 to generate a trigger 352 for the SpO₂ alarm 305. The alarm volume, modulation or tone may be altered to indicate priority, based upon the slope comparator output 322.

FIG. 4 illustrates a CO₂ alarm embodiment 400 that is responsive to SpO₂. In particular, morphology of the input CO₂ waveform 401 is utilized to trigger an alarm 405, and that alarm is also responsive to a falling SpO₂ 402. That is, if a pattern in the expired CO₂ waveform is detected and SpO₂ is trending down above a certain rate, then an alarm is triggered. For example, an increasing slope of the CO₂ plateau in combination with a downward trend of SpO₂ may trigger an alarm and alert a caregiver to the possibility of an airway obstruction.

As shown in FIG. 4, a pattern extractor 410 identifies salient features in the CO₂ waveform and generates a corresponding feature output 412. A pattern memory 420 stores one or more sets of predetermined waveform features to detect in the CO₂ input 401. The pattern memory 420 is accessed to provide a feature template 422. A feature comparator 430 compares the feature output 412 with the feature template 422 and generates a match output 432 indicating that a specific shape or pattern has been detected in the CO₂ waveform 401. In addition, a slope detector 440 determines the slope 442 of the SpO₂ input 402. A slope comparator 450 compares this slope 442 to a predetermined slope limit 404. If the downward trend of SpO₂ 402 is great enough, a slope exceeded output 452 is generated. If both the match output 432 and the slope exceeded output 452 are each asserted or "true," then a logical AND 460 generates a trigger output 462 to the alarm 470, which generates an alarm output 405.

FIG. 5 illustrates a combination embodiment 500 having a diagnostic output 505 responsive to both SpO₂ 501 and ETCO₂ 503 inputs. A SpO₂ slope detector 510 determines the slope 512 of the SpO₂ input 501 and can be made responsive to a negative slope, a positive slope or a slope absolute value. A first comparator 520 compares this slope 512 to a predetermined SpO₂ slope limit 502. If the trend of SpO₂ 501 is great enough, a SpO₂ slope exceeded output 522 is asserted. Likewise, an ETCO₂ slope detector 530 determines the slope 532 of the ETCO₂ input 503. A second comparator 540 compares this slope 532 to a predetermined ETCO₂ slope limit 504. If the downward trend of ETCO₂ 503 is great enough, an ETCO₂ slope exceeded output 542 is asserted. If both slope exceeded outputs 522, 542 are asserted or "true," a diagnostic output 505 is asserted.

In one embodiment, the slope detectors 510, 530 are responsive to a negative trend in the SpO₂ 501 and ETCO₂ 503 inputs, respectively. Accordingly, the diagnostic output 505 indicates a potential embolism or cardiac arrest. In another embodiment, the SpO₂ slope detector 510 is responsive to negative trends in the SpO₂ 501 input, and the ETCO₂ slope detector 530 is responsive to a positive trend in the ETCO₂ 503 input. Accordingly, the diagnostic output 505 indicates a potential airway obstruction. The diagnostic output 505 can trigger an alarm, initiate a display, or signal a nursing station, to name a few.

FIGS. 6A-B illustrate a physiological parameter system 600 utilizing pulse oximetry to control patient controlled analgesia (PCA). In particular embodiments, a control output 608 is responsive to pulse oximetry parameters 601 only if signal quality 603 is above a predetermined threshold 604. In FIG. 6A, the control output 608 can be used to lock-out patient controlled analgesia (PCA) if pulse oximetry param-

5

eter limits have been exceeded. If signal quality is so low that those parameters are unreliable, however, PCA is advantageously allowed. That is, the pulse oximetry parameters are not allowed to lock-out PCA if those parameters are unreliable. By contrast, in FIG. 6B, the control output 608 5 can be used to advantageously lock-out or disable patient controlled analgesia (PCA) if pulse oximetry parameter limits have been exceeded or if signal quality is so low that those parameters are unreliable.

As shown in FIG. 6A, pulse oximetry parameters 601 and corresponding limits 602 for those parameters are one set of inputs and a signal quality measures 603 and a corresponding lower limit 604 for signal quality are another set of inputs. The parameters 601 and corresponding limits 602 generate a combined output 703 that is asserted if any of the pulse oximetry parameter limits are exceeded. A comparator 610 compares the signal quality 603 input with a lower limit 604 generating a quality output 612 that is asserted if the signal quality 603 drops below that limit 604. An AND logic 620 generates a reset 622 if the combined output 702 is asserted and the quality output 612 is not asserted. The reset 622 resets the timer 630 to zero. A comparator 640 compares the timer output 632 to a predetermined time limit 606 and generates a trigger 642 if the time limit is exceeded. The trigger 642 causes the control 650 to generate the control output 608, enabling a patient controlled analgesia (PCA), for example. In this manner, the PCA is enabled if all monitored parameters are within set limits and signal quality is above its lower limit for a predetermined period of time. 25

As shown in FIG. 6B, the combined output 702, quality output 612, reset 622, timer 630, comparator 640 and control 650 are generated as described with respect to FIG. 6A, above. An OR logic 621 generates a reset 622 if either the combined output 702 or the quality output 612 is asserted. In this manner, the PCA is disabled for a predetermined period of time if any of the monitored parameters are outside of set limits or the signal quality is below its lower limit. 30

FIG. 7 illustrates combined limits 700 having SpO₂ parameters 601 and corresponding thresholds 602 as inputs and providing a combination output 702. In particular, if any parameter 601 exceeds its corresponding limit 602, the output of the corresponding comparator 710, 720, 740 is asserted. An OR logic 750 is responsive to any asserted output 712, 722, 742 to assert the combined output 702. For example, the combined output 702 may be asserted if SpO₂ 701 falls below a lower limit 709, pulse rate (PR) 703 rises above an upper limit 704 or PR 703 falls below a lower limit 706. 40

A physiological parameter system has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in the art will appreciate many variations and modifications. For example, the control output 608 (FIG. 6B) can be used to control (titrate) delivered, inspired oxygen levels to patients based upon pulse oximetry parameters, unless signal quality is so low that those parameters are unreliable. One of ordinary skill in the art will also recognize that the control output 608 (FIG. 6B) can be used to control patient delivery of any of various pharmacological agents and/or medical gases. 50 60

6

What is claimed is:

1. A physiological parameter system comprising:
one or more hardware processors configured to:

receive pulse oximetry parameters detected by a pulse oximeter, the pulse oximetry parameters including oxygen saturation and pulse rate measurements;
compare the oxygen saturation measurement with a saturation lower limit;
compare the pulse rate measurement with a pulse rate upper limit and a pulse rate lower limit;
generate a combined output based on the said comparison of the oxygen saturation and the comparison of the pulse rate measurement;
receive a quality indicator input relating to confidence in the pulse oximetry parameters;
compare the quality indicator input with a quality lower limit;
determine a lock out state of a patient controlled analgesia system based on the combined output and the comparison of the quality indicator input; and
generate a control output configured to lock out the patient controlled analgesia system based on the determination of the lock out state.

2. The physiological parameter system according to claim 1 wherein said control output disables the patient controlled analgesia system when confidence in the pulse oximetry parameters is low.

3. The physiological parameter system according to claim 2 wherein said control output prevents said the pulse oximetry parameters from disabling the patient controlled analgesia system when said quality indicator indicates confidence is low.

4. A physiological parameter method for automatic control of a patient controlled analgesia system using an electronic hardware processor, the method comprising:

under a control of a hardware processor:

receiving pulse oximetry parameters detected by a pulse oximeter, the pulse oximetry parameters including oxygen saturation and pulse rate;
comparing the oxygen saturation measurement with a saturation lower limit;
comparing the pulse rate measurement with a pulse rate upper limit and a pulse rate lower limit;
generating a combined output based on the said comparison of the oxygen saturation and the comparison of the pulse rate measurement;
receiving a quality indicator related to data confidence for the pulse oximetry parameters;
comparing the quality indicator input with a quality lower limit;
determining whether to lock a patient controlled analgesia system so as to disable a patient's control of the patient controlled analgesia system based on the combined output and the quality indicator;
outputting a control signal based on the said determination,

wherein said control signal is adapted to affect the operation of a the patient controlled analgesia system.

* * * * *

专利名称(译)	生理参数系统		
公开(公告)号	US10098591	公开(公告)日	2018-10-16
申请号	US14/275525	申请日	2014-05-12
[标]申请(专利权)人(译)	梅西莫股份有限公司		
申请(专利权)人(译)	Masimo公司		
当前申请(专利权)人(译)	Masimo公司		
[标]发明人	AL ALI AMMAR GRAYBEAL JOHN KIANI MASSI JOE E PETTERSON MICHAEL		
发明人	AL-ALI, AMMAR GRAYBEAL, JOHN KIANI, MASSI JOE E. PETTERSON, MICHAEL		
IPC分类号	A61B5/00 A61B5/1455 A61B5/083 A61M5/14 A61M5/172		
CPC分类号	A61B5/7275 A61B5/14551 A61B5/746 A61B5/7221 A61B2560/0276 A61B5/0836		
优先权	60/551165 2004-03-08 US 60/600640 2004-08-11 US		
其他公开文献	US20140330092A1		
外部链接	Espacenet		

摘要(译)

生理参数系统具有响应于一个或多个生理传感器的一个或多个参数输入。生理参数系统还可以具有与参数输入的置信度相关的质量指标。处理器适于组合参数输入，质量指示器和参数输入和质量指示器的预定限制，以便产生警报输出或控制输出或两者。

